One size fits all?: Ethical considerations for examining efficacy in first-in-human pluripotent stem cell studies

Molecular Therapy

Volumn 24, Issue 12, 2016, Pages 2039-2042

  Habets, Michelle G J L ^a   Van Delden, Johannes J M ^a   Niemansburg, Sophie L ^a   Atkins, Harold L ^b   Bredenoord, Annelien L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; EMBRYONIC STEM CELL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INFORMED CONSENT; LAW; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; RISK BENEFIT ANALYSIS; SAFETY; SPINAL CORD INJURY; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THERAPY EFFECT; TREATMENT RESPONSE; UNITED STATES; BIOTECHNOLOGY; CLINICAL RESEARCH; CLINICAL STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HISTOCOMPATIBILITY; MEDICAL SOCIETY; NONHUMAN; PHARMACEUTICS; RISK REDUCTION; INDUCED PLURIPOTENT STEM CELL;

HUMANS; INDUCED PLURIPOTENT STEM CELLS; PLURIPOTENT STEM CELLS;

EID: 85006253469     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.202     Document Type: Note

References (34)

1. Daniel C (2014). Reputation, and Power: Organizational Image, and Pharmaceutical Regulation at the FDA. Prince-Ton University Press: Princeton NJ.
2. US Department of Health Education, and Welfare (1977). Review Panel on New Drug Regulation. Interim Reports, vol. II, section A. Washington DC.
3. Le Boeuf F, Batenchuk C, Vähä-Koskela M, Breton S, Roy D, Lemay C, et al. (2013). Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 4: 1974.
4. Gooley TA, Martin PJ, Fisher LD, and Pettinger M (1994). Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin Trials 15: 450-462.
5. Habets MGJL, van Delden JJM, and Bredenoord AL (2016). Studying the lay of the land: views, and experiences of professionals in the translational pluripotent stem cell field. Regen. Med 11: 63-71.
6. Hess P (2012). Intracranial stem cell-based transplantation: reconsidering the ethics of phase 1 clinical trials in light of irreversible interventions in the brain. AJOB Neurosci 3: 3-13.
7. Miller FG, and Joffe S (2008). Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?. Clin Trials 5: 617-623.
8. Ross L (2006). Phase I research, and the meaning of direct benefit. J Pediatr 149: S20-S24.
9. Gilbert F, Harris AR, and Kapsa RMI (2014). Controlling brain cells with light: ethical considerations for optogenetic clinical trials. AJOB Neurosci 5: 3-11.
10. Hey SP, and Kimmelman J (2014). The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 24: 121-139.
11. Sipp D (2015). Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell 16: 353-356.
12. King NM (2000). Defining, and describing benefit appropriately in clinical trials. J Law Med Ethics 28: 332-343.
13. Hay M, Thomas DW, Craighead JL, Economides C, and Rosenthal J (2014). Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40-51.
14. US Food, and Drug Administration (2004). Innovation/Stagnation: Challenge, and Opportunity on the Critical Path to New Medical Products http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
15. Kimmelman J (2010). Gene Transfer, and the Ethics of First-in-Human Research : Lost in Translation. Cambridge University Press: Cambridge UK.
16. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. (2007). Clinical trials, and medical care: defining the therapeutic misconception. PLoS Med 4: e324.
17. Solbakk JH, and Zoloth L (2011). The tragedy of translation: the case of 'first use' in human embryonic stem cell research. Cell Stem Cell 8: 479-481.
18. Wirth E, Lebkowski JS, and Lebacqz K (2011). Response to Frederic Bretzner, et al., 'Target populations for first-in-human embryonic stem cell research in spinal cord injury.' Cell Stem Cell 8: 476-478.
19. Bretzner F, Gilbert F, Baylis F, and Brownstone RM (2011). Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8: 468-475.
20. Dresser R (2009). First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. J Law Med Ethics 37: 38-50.
21. Kimmelman J (2007). Stable ethics: enrolling non-Treatment-refractory volunteers in novel gene transfer trials. Mol Ther 15: 1904-1906.
22. Nada A, and Somberg J (2007). First-in-man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther 14: 594-604.
23. Habets MG, van Delden JJ, and Bredenoord AL (2016). Studying the lay of the land: views, and experiences of professionals in the translational pluripotent stem cell field. Regen Med 11: 63-71.
24. Bortin MM (1970). A compendium of reported human bone marrow transplants. Transplantation 9: 571-587.
25. Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau J-L, et al. (2014). Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. Biol Blood Marrow Transplant 20: 1217-1223.
26. US Congress. Office of Technology (1978). Assessing the Efficacy, and Safety of Medical Technologies http://digital.library.unt.edu/ark:/67531/metadc39383/.
27. Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, et al. (2012). Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30: 1144-1151.
28. Yarborough M, Tempkin T, Nolta J, and Joyce N (2012). The complex ethics of first in human stem cell clinical trials. AJOB Neurosci. 3: 14-16.
29. Woodcock J, and Woosley R (2008). The FDA Critical Path Initiative, and its influence on new drug development. Annu Rev Med 59: 1-12.
30. Kimmelman J, and Henderson V (2016). Assessing risk/benefit for trials using preclinical evidence: a proposal. J Med Ethics 42: 50-53.
31. Churchill LR, Nelson DK, Henderson GE, King NMP, Davis AM, Leahey E, et al. (2003). Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB Ethics Hum Res 25: 1-8.
32. Henderson GE, Davis AM, King NMP, Easter MM, Zimmer CR, Rothschild BB, et al. (2004). Uncertain benefit: investigators' views, and communications in early phase gene transfer trials. Mol Ther 10: 225-231.
33. Wages NA, and Tait C (2014). Seamless phase I/II adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat 25: 903-920.
34. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. (2007). A clinical development paradigm for cancer vaccines, and related biologics. J Immunother 30: 1-15.